Compare Western Alliance Bancorporation (WAL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Western Alliance Bancorporation vs Zoetis Inc — how do they compare? Western Alliance Bancorporation trades at $76.21 (market cap $8.24B), while Zoetis Inc trades at $73.54 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 3.7× Western Alliance Bancorporation's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Western Alliance Bancorporation for 3 Days and Zoetis Inc for 70 Days on average.
| WAL | ZTS | |
|---|---|---|
Market Cap | $8.24B | $30.20B |
Volume | 1,387,161 | 6,175,327 |
Sector | Financials | Health |
52-Week High | $96.08 | $147.53 |
52-Week Low | $66.70 | $69.09 |
Typical Hold Time | 3 Days | 70 Days |
Enterprise Value | $9.76B | $37.76B |
Dividend Yield | 2.23% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Western Alliance Bancorporation (WAL) trades at $74.35, down 2.29% today, with a bearish technical signal but strong fundamentals including a P/E of 8.52 and net income margin of 25.43%. Recent Q2 2026 earnings missed EPS estimates at $2.36, though revenue and profitability trends remain positive. The company launched WA VenueX, an institutional financial platform, and announced a $0.42 dividend for H2-2026.
Outlook is mixed: analyst consensus is strongly bullish with a $84.33 price target, but technical indicators signal near-term pressure. Key risks include interest rate sensitivity and regulatory changes, while institutional buying and solid valuation metrics support long-term upside potential.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.
Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
